打开APP

罗氏推出新一代病毒载量检测试剂盒cobas HIV-1和cobas HCV

  1. cobas检测平台
  2. 病毒载量检测
  3. 罗氏

来源:生物谷 2014-12-09 10:02

cobas 6800/8800系统代表了新一代分子诊断设备,提供了无与伦比的性能、无可比拟的灵活性、绝对的自动化,在病毒载量检测方面设定了新的行业标准。

2014年12月9日讯 /生物谷BIOON/ --罗氏(Roche)近日宣布在所有承认CE标识的市场推出应用于cobas 6800/8800系统的cobas HIV-1和cobas HCV检测试剂盒,这些试剂盒将为临床医生提供可依赖的高性能用于管理人类免疫缺陷病毒(HIV-1)或丙型肝炎病毒(HCV)感染者的临床治疗。这些试剂盒的上市,将扩展cobas 6800/8800系统菜单。

cobas 6800/8800系统代表了新一代分子诊断设备,能够提供无与伦比的性能、无可比拟的灵活性、绝对的自动化。借助于该系统的设计和临床应用,cobas HIV-1和cobas HCV检测试剂盒将为病毒载量的检测设定新的行业标准,并传递了罗氏致力于提供新的诊断工具以推进医疗社区对病毒疾病的了解及改善患者治的伟大使命。

未来几个月,罗氏还将推出cobas CMV(巨细胞病毒)和cobs HBV(乙肝病毒)检测试剂盒,这些试剂盒将完善cobas 6800/8800系统病毒载量监控检测的主要产品组合。这些运行于cobas 6800/8800系统的病毒载量组合产品,将提高实验室生产效率及做出快速临床决策的能力。

cobas HIV-1和cobas HCV试剂盒及cobas 6800/8800系统在所有承认CE标志的国家和地区上市,但目前尚未在美国上市。(生物谷Bioon.com)

英文原文:Roche launches next-generation viral load testing assays for new molecular diagnostic platforms in markets accepting the CE mark

cobas HIV-1 and HCV assays offer unparalleled performance on cobas 6800/8800 Systems

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the commercial availability of the cobas? HIV-1 and cobas HCV assays for use on the cobas 6800/8800 Systems¡ªexpanding the menu on the newest molecular diagnostic platforms from Roche with next generation viral load monitoring assays. The new assays offer the high performance that clinicians depend on to manage the treatment of patients infected with Human Immunodeficiency Virus (HIV-1) or Hepatitis C (HCV).

¡°The cobas 6800/8800 Systems represent the next generation of molecular diagnostic instruments that offer unparalleled performance, unmatched flexibility and absolute automation,¡± said Roland Diggelmann, COO of Roche Diagnostics. ¡°By virtue of their design and clinical utility, the cobas HIV-1 and cobas HCV tests set new industry standards for viral load assays, delivering on Roche¡¯s commitment to provide new diagnostic tools to advance the medical community¡¯s understanding about viral disease and improve the ability to treat patients.¡±

The assays launched today will be followed in the coming months by the cobas CMV and cobas HBV assays, which will complete the primary portfolio of viral load monitoring assays for the cobas 6800/8800 Systems. This viral load portfolio on the cobas 6800/8800 Systems will provide laboratories with improved productivity and the ability to deliver results for rapid clinical decisions.

The cobas HIV-1 and HCV assays and the cobas 6800/8800 Systems are commercially available in markets that recognize CE-Mark and are not currently available in the United States.

About the cobas 6800/8800 Systems

The cobas 6800 and 8800 Systems are fully automated solutions designed for blood donor screening, viral load monitoring, women¡¯s health and microbiology testing. They are available in medium and high throughput models, respectively. Based on the Nobel-prize winning PCR technology, the systems are designed to deliver increased automation and throughput with shorter time to results, providing users with greater testing flexibility to increase overall workflow efficiencies.

The systems provide up to 96 results in less than 3.5 hours, and a total of 384 results for the cobas 6800 and 960 results for the cobas 8800 in an 8 hours shift. Both systems allow for mixed batching, making it possible for labs to perform up to three tests in the same run with no pre-sorting required. The systems also enable up to eight hours (cobas 6800) and four hours (cobas 8800) of ¡°work-away¡± time* with minimal user interaction.

For more information about the systems, please visit www.cobas68008800.com.

* May vary based on workflow demands

About the Assays for the cobas 6800/8800 Systems

Assays for viral load monitoring

cobas HIV-1 is built upon the dual-target assay design from Roche. The test simultaneously amplifies and detects two separate regions of the HIV-1 genome, which are not subject to selective drug pressure, allowing for more reliable results to confidently and effectively quantify the amount of HIV-1 RNA in a patient's blood.

cobas HCV employs Roche¡¯s unique dual-probe approach to provide an extra layer of protection against mutations that can occur in the viral genome and is designed to accurately detect and quantify hepatitis C virus ribonucleic acid (RNA) with state-of-the-art sensitivity in order to assess a patient¡¯s response to antiviral therapy.

Assays for donor screening

cobas MPX is a real-time PCR multiplex test covering five critical viral targets: HIV-1 Group M, HIV-1 Group O, HIV-2, HCV and HBV, from a single sample. It offers real-time detection and identification of HIV, HCV and HBV, eliminating both the need for discriminatory testing and the potential for discrepant results. Plus, the dual-target approach with amplification of separate regions of HIV-1, and dual probes for HCV, improve coverage of new virus variants.

cobas WNV is a real-time PCR test for West Nile virus (WNV) that is highly sensitive for both WNV lineages 1 and 2. It also provides broad coverage of other flaviviruses that cause transfusion-transmitted infectious diseases.

cobas HEV is a real-time PCR test for hepatitis E virus (HEV), providing broad coverage of all 4 major HEV genotypes.

About HIV-1

According to the World Health Organization (WHO), there were 35 million people living with HIV around the world in 2012. That same year 2.5 million people became newly infected with HIV worldwide.1 For the most impacted region of Sub-Saharan Africa nearly 1 in every 20 adults or 69% of all people living in this region are with HIV positive.

Diagnosis, highly active antiretroviral treatment (HAART) and viral load testing¡ªtesting to determine the amount of circulating HIV¡ªhave contributed to a steady increase in life expectancy for HIV infected people of 13 years.2

About Hepatitis C

According to the World Health Organization, HCV affects some 200 million people globally. Approximately 170 million people are chronic carriers of the hepatitis C virus, and most do not know they are infected. The disease can ultimately result in cirrhosis, liver failure and hepatocellular carcinoma, which together are responsible for hundreds of thousands of deaths each year.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world¡¯s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche¡¯s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organisation Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.

In 2013 the Roche Group employed over 85,000 people worldwide, invested 8.7 billion Swiss francs in R&D and posted sales of 46.8 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->